ConductScience.org, home

Paper35166158

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.

Gukasyan N and 6 others. J Psychopharmacol, 2022. Cited by 286 papers, by iCite.

Cite this record

ConductScience Library. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Papers, record 35166158. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35166158

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
PubMed
Journal
J Psychopharmacol
PubMed
Year
2022
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
286
iCite
Relative citation ratio, by iCite
29.4
iCite
Revised in PubMed
2026-01-27
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gukasyan NNataliehttps://orcid.org/0000-0003-3567-1421
2Davis AKAlan Khttps://orcid.org/0000-0003-4770-8893
3Barrett FSFrederick S
4Cosimano MPMary P
5Sepeda NDNathan D
6Johnson MWMatthew W
7Griffiths RRRoland Rhttps://orcid.org/0000-0001-5185-7854

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antidepressive AgentsMajor topic
Major Depressive DisorderMajor topic
HallucinogensMajor topic
PsilocybinMajor topic
Adult
Aged
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Male
Middle Aged
Prospective Studies
Psychiatric Status Rating Scales
Psychotherapy
Time Factors
Treatment Outcome
Young Adult

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
T32 DA007209NIDA NIH HHSUnited StatesT32DA007209PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT06303739Psilocybin-Assisted Therapy in Treatment-Resistant DepressionBackgroundClinicalTrials.gov
NCT07710027Identification of a Safe and Non-Psychedelic Dose of PsilocybinBackgroundClinicalTrials.gov

Download CSV of trials

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129753748The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.Neuropharmacology2018https://conductscience.org/library/papers/29753748PubMed
226926127Potential Risks of Poorly Monitored Ketamine Use in Depression Treatment.Am J Psychiatry2016https://conductscience.org/library/papers/26926127PubMed
325563443Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.Curr Drug Abuse Rev2014https://conductscience.org/library/papers/25563443PubMed
432864325Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety.J Contextual Behav Sci2020https://conductscience.org/library/papers/32864325PubMed
527261367Ketamine abuse potential and use disorder.Brain Res Bull2016https://conductscience.org/library/papers/27261367PubMed
630496104
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
Lancet2018https://conductscience.org/library/papers/30496104PubMed
719045960Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies.J Consult Clin Psychol2008https://conductscience.org/library/papers/19045960PubMed
833726522Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.Am J Psychiatry2021https://conductscience.org/library/papers/33726522PubMed
932500212Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan.Psychopharmacology (Berl)2020https://conductscience.org/library/papers/32500212PubMed
1032061748Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.Behav Brain Res2020https://conductscience.org/library/papers/32061748PubMed
1117640154Prevalence and management of treatment-resistant depression.J Clin Psychiatry2007https://conductscience.org/library/papers/17640154PubMed
1227909164Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.J Psychopharmacol2016https://conductscience.org/library/papers/27909164PubMed
1328013125The effect of treatment as usual on major depressive disorder: A meta-analysis.J Affect Disord2017https://conductscience.org/library/papers/28013125PubMed
1410671391Multiple recurrences of major depressive disorder.Am J Psychiatry2000https://conductscience.org/library/papers/10671391PubMed
1529020861
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.
J Psychopharmacol2018https://conductscience.org/library/papers/29020861PubMed
1621820991Prevalence and clinical course of depression: a review.Clin Psychol Rev2011https://conductscience.org/library/papers/21820991PubMed
1718593735Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.J Psychopharmacol2008https://conductscience.org/library/papers/18593735PubMed
1818593734Human hallucinogen research: guidelines for safety.J Psychopharmacol2008https://conductscience.org/library/papers/18593734PubMed
1933852780Trial of Psilocybin versus Escitalopram for Depression.N Engl J Med2021https://conductscience.org/library/papers/33852780PubMed
2033146667Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.JAMA Psychiatry2021https://conductscience.org/library/papers/33146667PubMed

See all 37 referencesDownload CSV of references

Cited by159

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 286 citations.

PMIDTitleJournalYearIn PapersSource
42900476Clinical Evidence on Psilocybin and Its Representation in Media Reporting: A Systematic Review.JAMA Netw Open2026https://conductscience.org/library/papers/42900476PubMed
42818834Exploring the potential of psychedelics in brain injury recovery: a thematic analysis of participant narratives.Front Neurol2026https://conductscience.org/library/papers/42818834PubMed
42812990Psilocybin and ayahuasca in treatment-resistant depression: clinical evidence, methodological constraints and ethical challenges: a narrative review.Front Psychiatry2026https://conductscience.org/library/papers/42812990PubMed
42794483Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Review.Int J Mol Sci2026https://conductscience.org/library/papers/42794483PubMed
42653026Psychedelic Safety and Clinical Outcomes Across Exposure Patterns: A Structured Narrative Review.Life (Basel)2026https://conductscience.org/library/papers/42653026PubMed
42506248Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions.J Fungi (Basel)2026https://conductscience.org/library/papers/42506248PubMed
42504298Conceptual analysis of mechanisms and methods in psychedelic clinical trial design: a narrative review.Ther Adv Psychopharmacol2026https://conductscience.org/library/papers/42504298PubMed
42357539DESI-MSI-Based Multi-Organ Distribution Mapping of Psilocin in Zebrafish.Molecules2026https://conductscience.org/library/papers/42357539PubMed
42350785Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions.Mol Psychiatry2026https://conductscience.org/library/papers/42350785PubMed
42346087Sex Differences in Depression: Adult Cytogenesis as Potential Target for Precision Psychiatry.Cells2026https://conductscience.org/library/papers/42346087PubMed
42342649Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health care.Transl Psychiatry2026https://conductscience.org/library/papers/42342649PubMed
42201843Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial.Psychother Psychosom2026https://conductscience.org/library/papers/42201843PubMed
42196212Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging-From Depression to Neurodegeneration.Int J Mol Sci2026https://conductscience.org/library/papers/42196212PubMed
42138922Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial.JAMA Netw Open2026https://conductscience.org/library/papers/42138922PubMed
42093782Catatonia Associated With First-Time Psilocybin Exposure: A Case Report.Cureus2026https://conductscience.org/library/papers/42093782PubMed
41969367Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer.Nat Ment Health2024https://conductscience.org/library/papers/41969367PubMed
41918771A scoping review of mystical-type experiences and mood symptom outcomes in psychedelic therapy clinical trials: comparing life-threatening disease and depressive populations.Ther Adv Psychopharmacol2026https://conductscience.org/library/papers/41918771PubMed
41854988Psilocybin effects on brain functional connectivity: a systematic review of fMRI studies.Discov Ment Health2026https://conductscience.org/library/papers/41854988PubMed
41828429Predictors of the Effectiveness of Psychedelics in Treating Depression-A Scoping Review.Int J Mol Sci2026https://conductscience.org/library/papers/41828429PubMed
41707717Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial.J Affect Disord2026https://conductscience.org/library/papers/41707717PubMed

See all 159 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
GRAP29402PubTator's text mininghttps://conductscience.org/library/genes/9402

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35166158

GET https://conductscience.org/api/papers/v1/35166158/references?page=2